Business
Boehringer Bets Over $1B on AI That Reads a Hidden Layer of Cancer Biology
Envisagenics uses machine learning to mine “RNA splicing” — a largely untapped source of cancer targets — and Boehringer Ingelheim is paying up to $1 billion to turn those targets into precision therapies.